Aller au contenu principal
xMedica

NCT07817251ClinicalTrials.gov

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…

Phase 3210 participants recherchés40 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 210 participants (target), run at 40 sites.

How this score is built
  • Enrolment22/40

    210 participants (target)

  • Site count19/25

    40 sites

  • Country count0/15

    Single country

  • Planned duration4/10

    Planned over about 10 months

  • Sponsor scale9/10

    Novo Nordisk A/S has led 339 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Affections

  • Diabetes Mellitus, Type 2

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement210 participants recherchés

Promoteur et collaborateurs

  • Novo Nordisk A/S Promoteur

Groupes et interventions

  • CagriSema dose 1EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.

  • CagriSema dose 2EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.

  • CagriSema dose 3EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.

Interventions

  • Médicament CagriSema

    CagriSema will be administered s.c. once weekly.

Critères de jugement

  1. Critère de jugement principal

    Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Délai From baseline (Week 0) to end of treatment (Week 16)

  2. Critère de jugement secondaire

    Number of TEAEs

    Measured as count of events.

    Délai From baseline (Week 0) to end of study (Week 22)

  3. Critère de jugement secondaire

    Number of TEAEs

    Measured as count of events.

    Délai From baseline (Week 0) to Week 8

  4. Critère de jugement secondaire

    Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)

    Measured as count of episodes.

    Délai From baseline (Week 0) to end of study (Week 22)

  5. Critère de jugement secondaire

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Délai From baseline (Week 0) to end of study (Week 22)

  6. Critère de jugement secondaire

    Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)

    Measured as count of episodes.

    Délai From baseline (Week 0) to Week 8

  7. Critère de jugement secondaire

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Délai From baseline (Week 0) to Week 8

  8. Critère de jugement secondaire

    Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)

    Measured as count of participants.

    Délai From baseline (Week 0) to end of treatment (Week 16)

Dates

Dates
Date de début16 septembre 2026 (réelle)
Achèvement principal9 juin 2027 (estimée)
Achèvement21 juillet 2027 (estimée)
Première publication14 septembre 2026 (réelle)
Dernière mise à jour30 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

37 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Albuquerque Clinical Trials Inc.AlbuquerqueNew MexicoEn recrutement
Amarillo Med Spec LLPAmarilloTexasEn recrutement
Texas Diabetes & EndocrinologyAustinTexasEn recrutement
Northern Pines Hlth Ctr, PCBuckleyMichiganEn recrutement
North Texas Endocrine CenterDallasTexasEn recrutement
Northeast Research InstituteFleming IslandFloridaEn recrutement
Diabetes and Thyroid Center of Fort WorthFort WorthTexasEn recrutement
Ark Clinical ResearchFountain ValleyCaliforniaEn recrutement
Gilbert Center For Family MedicineGilbertArizonaEn recrutement
Thrive Clinical Research GroupGlendoraCaliforniaEn recrutement
PharmQuest Life Sciences LLCGreensboroNorth CarolinaEn recrutement
AGA Clinical TrialHialeahFloridaEn recrutement
East West Med Res InstHonoluluHawaiiEn recrutement
JCCT- Juno NW HoustonHoustonTexasEn recrutement
Sante Clinical ResearchKerrvilleTexasEn recrutement
Scripps Whittier Diabetes InstLa JollaCaliforniaEn recrutement
Palm Research Center Inc-VegasLas VegasNevadaEn recrutement
DCOL Ctr for Clin ResLongviewTexasEn recrutement
Downtown LA Res Ctr. Inc.Los AngelesCaliforniaEn recrutement
Advanced Medical ResearchMaumeeOhioPas encore en recrutement
Adult Medicine of Lake County, IncMt. DoraFloridaEn recrutement
Clinical Research AssociatesNashvilleTennesseeEn recrutement
Tidewater Physicians Multispecialty GroupNewport NewsVirginiaEn recrutement
Alliance for Multispecialty ResearchNewtonKansasEn recrutement
North Hills Medical Research IncNorth Richland HillsTexasEn recrutement
Valley Clinical Trials, Inc.NorthridgeCaliforniaEn recrutement
Optimal Research SitesOrange CityFloridaEn recrutement
Dream Team Clinical ResearchPomonaCaliforniaEn recrutement
Clinical Trials Research_SacramentoSacramentoCaliforniaEn recrutement
J.Lewis Research IncSalt Lake CityUtahEn recrutement
NE Clin Res of San AntonioSan AntonioTexasPas encore en recrutement
Linda Vista Health Care CtrSan DiegoCaliforniaEn recrutement
Diabetes & Endo Treatment SpecSandy CityUtahPas encore en recrutement
Endeavor HealthSkokieIllinoisEn recrutement
Chrysalis Clinical ResearchSt. GeorgeUtahEn recrutement
Cotton O'Neil Diabetes & EndocrinologyTopekaKansasEn recrutement
Chase Medical Research LLCWaterburyConnecticutEn recrutement
Iowa Diabetes & Endo Res CtrWest Des MoinesIowaEn recrutement
Metabolic Research Institute IncWest Palm BeachFloridaEn recrutement
Accellacare WilmingtonWilmingtonNorth CarolinaEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 30 septembre 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 30 septembre 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING